Beta isomer comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms. Its structure consists of a nicotinamide group linked to a ribose sugar that carries a phosphate group. NMN is an intermediate in the biosynthesis of nicotinamide adenine dinucleotide, or NAD+, a coenzyme involved in many metabolic reactions. The abbreviation usually refers to the beta anomer, though related forms can exist. In scientific literature, NMN is distinct from nicotinamide riboside, another NAD+ precursor.
Stability studies indicate that NMN is sensitive to heat, light, and pH extremes. In aqueous solution, hydrolysis can cleave the phosphate linkage or convert NMN to related nicotinamide derivatives, with degradation accelerating at elevated temperatures and alkaline conditions. Solid material is generally more stable when kept dry and cold, and research-grade supplies are often stored at minus twenty degrees Celsius or lower, protected from light and moisture. Repeated freeze-thaw cycles of solutions can promote degradation, so aliquoting is a common laboratory practice. The exact shelf life depends on purity, counterion, packaging, and storage history.
Quality control for NMN focuses on identity, purity, and the absence of harmful contaminants. Certificates of analysis may report high-performance liquid chromatography purity, mass spectrometry identity, residual solvents, heavy metals, and microbial limits, depending on grade and intended use. Because NMN can exist as different isomers, salts, or hydrates, specification sheets should state the exact form being tested. There is no single globally harmonized purity standard for NMN products. Open questions include which degradation products are most relevant under real-world storage and how analytical results from different laboratories can be compared reliably.
Analytical measurement of NMN typically uses reversed-phase high-performance liquid chromatography with ultraviolet detection near 260 nm. Mass spectrometry, often coupled to liquid chromatography, provides sensitive quantification and confirmatory identification in biological matrices. Nuclear magnetic resonance spectroscopy is used to verify molecular structure and distinguish related nucleotides. Because NMN is polar and poorly retained on conventional reversed-phase columns, ion-pairing reagents or hydrophilic interaction chromatography are sometimes employed. Reported purity values depend on the chosen method, calibration standard, and whether related substances are resolved.
| Property | Value | Notes |
|---|---|---|
| Chemical name | Nicotinamide mononucleotide | Common name; beta form often denoted beta-NMN |
| Chemical formula | C11H15N2O8P | As free acid; salt forms differ |
| Molar mass | 334.22 g/mol | Calculated for the free acid |
| CAS Registry Number | 1094-61-7 | For beta-nicotinamide mononucleotide |
| Biochemical role | NAD+ intermediate | Participates in the salvage biosynthesis pathway |
Small amounts of NMN occur in some foods, including certain vegetables, fruits, and animal products, though the quantities are generally low and variable. Human cells also synthesize NMN internally from nicotinamide and other precursors. Research interest increased after studies examined whether raising NAD+ levels affects metabolism and aging-related pathways in animals. Evidence in humans remains limited and mixed for many outcomes, and questions about effective absorption, tissue delivery, and long-term effects are still open. Regulatory status differs by country, with some markets treating NMN as a supplement ingredient and others restricting its sale.
Nicotinamide mononucleotide, usually shortened to NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide base linked to a ribose sugar that carries a phosphate group. In cells, NMN serves as an intermediate in the salvage pathway that produces nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in many oxidation-reduction reactions, NMN sits near central metabolic processes. The compound is not a drug in most jurisdictions and is discussed mainly in biochemistry and nutrition research.
Analytical identification of NMN commonly uses high-performance liquid chromatography with ultraviolet detection, liquid chromatography-mass spectrometry, and nuclear magnetic resonance spectroscopy; HPLC can estimate purity by peak area, while mass spectrometry confirms molecular mass and fragmentation. NMR provides structural confirmation. Because NMN is charged, ion-pairing reagents or hydrophilic interaction liquid chromatography columns can improve retention and peak shape. In biological samples, LC-MS/MS with stable isotope internal standards is often used to quantify NMN and related NAD+ metabolites. Method validation is important because matrix effects and rapid enzymatic interconversion can complicate measurements.
Quality control for NMN typically checks identity, assay purity, residual solvents, heavy metals, and microbial limits, depending on the intended use and market. A certificate of analysis may report appearance, solubility, water content, and storage recommendations. Independent verification can compare chromatographic retention time and mass spectrum against a certified reference standard. Regulatory expectations differ between research chemicals, dietary ingredients, and pharmaceutical products. Impurity profiles and stability data are often requested for product approval, and open questions remain about how best to standardize NMN measurements across laboratories.
Research on NMN includes cell studies, animal experiments, and a growing number of human trials. Many early findings come from mice, where changes in NAD+ levels and metabolic markers have been reported. Human data are more limited, and questions remain about effective routes of administration, tissue distribution, and long-term effects. Some trials measure NAD+ in blood or tissue, while others assess physical function or metabolic outcomes. Regulatory status differs between countries, and NMN is not universally approved as a dietary supplement or therapeutic agent.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring with a ribose sugar and a phosphate group. The compound appears in cells across many organisms as an intermediate in the production of nicotinamide adenine dinucleotide, or NAD+. Because NMN sits close to NAD+ in metabolism, it has drawn interest in biochemistry and aging research. The molecule is not a dietary essential nutrient in the classical sense, and its presence in food is generally low and variable.
=== Potential technology === A new family of LEDs are based on the semiconductors called perovskites. In 2018, less than four years after their discovery, the ability of perovskite LEDs (PLEDs) to produce light from electrons already rivaled those of the best performing OLEDs. They have a potential for cost-effectiveness as they can be processed from solution, a low-cost and low-tech method, which might allow perovskite-based devices that have large areas to be made with extremely low cost. Their efficiency is superior by eliminating non-radiative losses, in other words, elimination of recombination pathways that do not produce photons; or by solving outcoupling problem (prevalent for thin-film LEDs) or balancing charge carrier injection to increase the EQE (external quantum efficiency). The most up-to-date PLED devices have broken the performance barrier by shooting the EQE above 20%. In 2018, Cao et al. and Lin et al. independently published two papers on developing perovskite LEDs with EQE greater than 20%, which made these two papers a mile-stone in PLED development. Their device have similar planar structure, i.e. the active layer (perovskite) is sandwiched between two electrodes. To achieve a high EQE, they not only reduced non-radiative recombination, but also utilized their own, subtly different methods to improve the EQE. In the work of Cao et al., researchers targeted the outcoupling problem, which is that the optical physics of thin-film LEDs causes the majority of light generated by the semiconductor to be trapped in the device.
==== Commander of the Royal Victorian Order (CVO) ==== Ian Angus Campbell, Lord-Lieutenant of Dorset. Sophia Louisa Densham, , Private Secretary to Her Majesty The Queen. Patric Laurence Dickinson, , Secretary of the Order of the Garter. Dr Veronica Mary Geneste Ferguson, , Surgeon-Oculist to Queen Elizabeth II. Alastair Gilbert Martin, Secretary, Duchy of Cornwall. Malcolm Ian, Baron Offord of Garvel, lately Trustee, The Duke of Edinburgh's Award Scheme. Sir Antonio Pappano, Conductor of the Coronation Orchestra, on the occasion of the Coronation of Their Majesties The King and The Queen. Professor James Roy Robertson, , lately Apothecary to His Majesty The King at the Palace of Holyroodhouse.
Metabolomics: Scientific study of chemical processes involving metabolites. It is a "systematic study of the unique chemical fingerprints that specific cellular processes leave behind", the study of their small-molecule metabolite profiles Metabonomics: The quantitative measurement of the dynamic multiparametric metabolic response of living systems to pathophysiological stimuli or genetic modification
In March 2021, Columbia University professor Thomas J. Christensen wrote that the cold war between the US and China "is unlikely" in comparison to the original Cold War, citing China's prominence in the "global production chain" and absence of the authoritarianism vs. liberal democracy dynamic. Christensen further advised those concerned about the tensions between the two nations to research China's role in the global economy and its "foreign policy toward international conflicts and civil wars" between liberal and authoritarian forces. In September 2021, former Portuguese defence and foreign minister Paulo Portas described the announcement of the AUKUS security pact and the ensuing unprecedented diplomatic crisis between the signatories (Australia, the United Kingdom, and the United States) and France (which has several territories in the Indo-Pacific) as a possible formal starting point of a new Cold War. On 7 November 2021, President Biden's national security adviser Jake Sullivan stated that the US does not pursue system change in China anymore, marking a clear break from the China policy pursued by previous US administrations. Sullivan said that the US is not seeking a new Cold War with China, but is looking for a system of peaceful coexistence. In November 2021, Hal Brands and Yale professor John Lewis Gaddis wrote in Foreign Affairs that while it was no longer debatable that the United States and China has been entering into their "own new cold war", it was not clear that the world has also been following suit and entering into a new cold war.
Sources: en.wikipedia.org
While European ETSI standards have supported WMAS for several years, the U.S. Federal Communications Commission (FCC) officially adopted rules in February 2024 to allow WMAS operation in the United States. This regulatory change led to the introduction of wideband digital platforms such as Sennheiser’s Spectera and Shure’s Axient Digital PSM (ADPSM), which allow for bidirectional audio and increased spectral efficiency at large-scale events.
protoplast A plant, fungal, or bacterial cell which has had its cell wall removed by mechanical, chemical, or enzymatic means; or the complete contents (the protoplasm) of an intact cell excluding the cell wall.
=== Magnetic drug targeting === An important task in cancer research is developing more precise methods for delivering medicine to affected areas. One method involves binding of medicine to biologically compatible magnetic particles (such as ferrofluids), which are guided to the target through careful placement of permanent magnets on the exterior of the body. Magnetohydrodynamic equations and finite element analysis are used to study interactions between magnetic fluid particles in the bloodstream and the external magnetic field.
=== 10 July === One person was killed in a Russian attack in Voznesensk, Mykolaiv Oblast. Eight others, including the town's mayor Yevhenii Velychko, were injured. DeepStateMap.Live reported that Russia had captured the village of Yevhenivka. Portugal agreed to supply Ukraine with 220 million euros in assistance during 2024 and 2025. Norway pledged six F-16s to Ukraine. British Prime Minister Keir Starmer said that Ukraine can use Storm Shadow missiles “against military targets within Russian territory”. An unspecified number of F-16 fighter jets were reported to be en route to Ukraine with the expectation that they will be operational by summer 2024.
Additionally, CAM providers are concerned by the closure of other CAM laboratories under CLIA, and have sought to avoid detection. Some CAM providers and laboratory personnel have not had exposure to laboratory curriculum and are unaware of CLIA requirements. CLIA is largely reliant on laboratories to self-identify themselves for enrollment. Providers of CAM laboratories have opposed CLIA oversight and suggested they be regulated by their peers or by a CAM-specific division. CAM providers have stated that they should be exempt from CLIA since CAM laboratories do not participate in health insurance. Others claim that they are exempt from CLIA because the tests are performed solely for research purposes and not used in patient care and treatment decisions. Several pathologists have stated that CAM testing falls within the scope of their medical license and should not be regulated under CLIA. CLIA provisions are geared towards CLIA-certified laboratories, but not for those that have not enrolled. When a CAM laboratory is found to be operating without a CLIA certificate, they are sent a cease and desist letter to stop testing until the laboratory is CLIA certified. There are no administrative remedies available to CMS when a laboratory refuses to enroll in CLIA and refuses to cease testing. CMS cannot impose monetary or other administrative penalties on laboratories that defy the law, but can only refer cases to other Federal or State agencies.
Sources: en.wikipedia.org
Partial agonism and signaling bias describe distinct pharmacological properties: partial agonism refers to the maximum response produced relative to a reference full agonist, whereas signaling bias describes the relative preference for different intracellular signaling pathways activated by the same receptor. Activation of MOR primarily couples the receptor to inhibitory Gi/o proteins, resulting in inhibition of adenylyl cyclase, reduced intracellular cyclic AMP (cAMP), modulation of potassium and calcium channels, and decreased neuronal excitability and neurotransmitter release. β-Arrestin recruitment represents a partially distinct signaling and regulatory pathway involved in receptor desensitization, trafficking, and internalization. Consequently, a ligand may display partial efficacy for G-protein signaling while producing substantially weaker β-arrestin recruitment. MORs may also form receptor homomers containing more than one receptor protomer. Therefor occupancy of one protomer by a partial agonist does not necessarily prevent a second ligand from occupying the other orthosteric binding site of the second protomer. Thus, a 48%-efficacy partial agonist and a second partial agonist exhibiting 66% efficacy would occupy the second separate protomer within the same receptor complex. Buprenorphine was patented in 1965, FDA approved for medical use as an analgesic in 1981, and FDA approved for treating opioid use disorder in 2002. It is on the World Health Organization's List of Essential Medicines.
== History == Adalimumab was the first fully human monoclonal antibody approved by the US Food and Drug Administration (FDA). It is derived from phage display. Adalimumab was discovered as a result of a collaboration between BASF Bioresearch Corporation and Cambridge Antibody Technology, U.K., itself a collaboration of the government-funded Medical Research Council and three academics, which began in 1993. Initially named D2E7, it was then further manufactured at BASF Bioresearch Corporation, developed by BASF Knoll (BASF Pharma), and ultimately manufactured and marketed by Abbott Laboratories after Abbott's acquisition of BASF Pharma. On 1 January 2013, Abbott split into two companies, one retaining the Abbott name and the other named AbbVie. As a result, AbbVie took over development and marketing of Humira. The brand name Humira stands for "human monoclonal antibody in rheumatoid arthritis", and was named by one of Abbott's employees, Richard J. Karwoski, who was also responsible for leading the effort to get Humira approved by the FDA. It is the third TNF inhibitor, after infliximab and etanercept, to be approved in the United States. It is constructed from a fully human monoclonal antibody, while infliximab is a mouse-human chimeric antibody and etanercept is a TNF receptor-IgG fusion protein. The drug candidate was discovered initially using CAT's phage display technology and named D2E7. The key components of the drug were found by guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen TNF.
{\displaystyle {\underset {\text{fluorapatite}}{{\ce {Ca5(PO4)3F}}}}+{\ce {5 H2SO4 + 10 H2O}}\longrightarrow {\underset {{\text{calcium sulfate}} \atop {\text{dihydrate}}}{{\ce {5 CaSO4*2H2O}}}}+{\ce {HF + 3 H3PO4}}}
The Algal Collection of the US National Herbarium (located in the National Museum of Natural History) consists of approximately 320,500 dried specimens, which, although not exhaustive (no exhaustive collection exists), gives an idea of the order of magnitude of the number of algal species (that number remains unknown). Estimates vary widely. For example, according to one standard textbook, in the British Isles, the UK Biodiversity Steering Group Report estimated there to be 20,000 algal species in the UK. Another checklist reports only about 5,000 species. Regarding the difference of about 15,000 species, the text concludes: "It will require many detailed field surveys before it is possible to provide a reliable estimate of the total number of species ..." Regional and group estimates have been made, as well:
Sources: en.wikipedia.org
Nicotinamide mononucleotide is a nucleotide intermediate in the biosynthesis of NAD+. It consists of nicotinamide attached to a ribose phosphate unit. NMN occurs naturally in cells and is present at low levels in some foods.
NMN is a direct precursor in the NAD+ salvage pathway. Enzymes called NMNAT convert NMN into NAD+, a coenzyme used in metabolism and cell signaling. Raising NMN may increase NAD+ in some experimental settings, but the effect depends on tissue and organism.
No. Nicotinamide riboside is a related compound that lacks the phosphate group present in NMN. Cells can convert nicotinamide riboside into NMN, and both compounds feed into NAD+ production through overlapping routes.
Liquid chromatography coupled with tandem mass spectrometry is widely used because it can separate NMN from related nucleotides and quantify low concentrations. Stable isotope-labeled internal standards help correct for matrix effects and recovery losses. Ultraviolet detection alone is less specific for complex biological matrices.